LOs for PHRm3102 
# Therapeutics Curriculum 
# 8 May 2025

# The aim of this sheet is to map subjects and condition-specific learning objectives against the American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum 2023

- system: Cardiovascular conditions
	 tiers:
	 
	 - tier: 1 conditions:
	 	 
	 	 - name: Arrhythmias, atrial
	 	 	 subjects:
	 	 	 - PHRM2102
Identify the signs, symptoms, and types of arrhythmias, including atrial fibrillation.
Describe the underlying causes and risk factors for atrial fibrillation and other arrhythmias.
Explain the pharmacological and non-pharmacological treatment options for arrhythmias.
Understand the role of anticoagulation in atrial fibrillation and stroke prevention.
Interpret ECG findings relevant to common arrhythmias.
Discuss the pharmacist?s role in monitoring therapy and educating patients with arrhythmias.
Recognize potential drug interactions and adverse effects associated with antiarrhythmic medications.
	 	 	 - PHRM3102 
	 	 As above ? as well as: 
Evaluate patient-specific factors (e.g., age, renal function, comorbidities, adherence) that influence therapeutic decision-making in management of arrhythmias
	 	 - name: Chronic coronary disease (formerly stable ischemic heart disease)
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 los:
	 	 	 - Evaluate pharmacotherapeutic management of secondary prevention following ACS
	 	 	 - Identify MOA, adverse effects and outcome evidence for statins, ACEI/ARB, betablockers, [more?]
	 	 	 - Evaluate cardiac risk

	 	 - name: Dyslipidemia
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM4101
	 	 	 los:
	 	 	 - Describe treatment goals
	 	 	 - Evaluate cardiac risks including interpreting lab test
	 	 	 - Idenitfy MOA, adverse effect and outcome evidence for statins, ezitemide

	 	 - name: Heart failure, chronic (why is acute separate?) I have written goals as one but James we can separate out if you like.
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 	 	 Describe the pathophysiology and classification of heart failure, including distinctions between HFrEF, HFmrEF, and HFpEF.
	 	 	 	 	 Identify common signs and symptoms of heart failure and explain their clinical significance in diagnosis and monitoring.
	 	 	 	 	 Explain the pharmacological and non-pharmacological therapeutic goals in the management of heart failure, including:
	 	 	 	 	 Reducing morbidity and mortality, Improving quality of life and functional status, inimizing hospitalisations and disease progression
	 	 	 	 	 Demonstrate knowledge of guideline-directed medical therapy for heart failure, including the four pillars of medication management:
	 	 	 	 	 	 	 ACE inhibitors/ARBs/ARNIs
	 	 	 	 	 	 	 Beta-blockers
	 	 	 	 	 	 	 Mineralocorticoid receptor antagonists (MRAs)
	 	 	 	 	 	 	 SGLT2 inhibitors

	 	 	 - PHRM4101
	 	 	 - PHRM3102
	 	 	 	 	 	 Describe the pathophysiology and classification of heart failure, including distinctions between HFrEF, HFmrEF, and HFpEF.
	 	 	 	 	 	 In addition to above (PHRM2102)
	 	 	 	 	 	 	 	 Evaluate patient-specific factors (e.g., renal function, comorbidities, adherence) that influence therapeutic decision-making in heart failure.
	 	 	 	 	 	 	 	Apply evidence-based guidelines to develop and adjust individualized pharmacotherapy plans for patients with heart failure.
	 	 
	 	 - name: Hypertension
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 	 Explain the pathophysiology and classification of hypertension, including primary and secondary hypertension, and the significance of systolic vs. diastolic blood pressure.
	 	 	 	 Interpret blood pressure readings using current diagnostic thresholds (e.g., Ú130/80 mmHg per ACC/AHA guidelines) and understand the implications for cardiovascular risk.
Describe the therapeutic goals of hypertension management, including:
Reducing the risk of cardiovascular events (e.g., stroke, myocardial infarction)
Preventing or slowing progression of target organ damage (e.g., kidney, heart, brain)
Achieving and maintaining individualized blood pressure targets
Identify first-line and adjunctive pharmacological therapies for hypertension, including:
ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics
Beta-blockers, aldosterone antagonists, and other agents for specific indications

	 	 	 
	 	 	 - PHRM4101
	 	 	 
	 	 	 - PHRM3102
	 	 	 	 	 Apply evidence-based guidelines (e.g., ACC/AHA, ISH, Australian guidelines) to develop individualized treatment plans for patients with hypertension. 
	 	 	 	 	 Evaluate patient-specific factors (e.g., age,frailty, comorbidities, ethnicity, lifestyle) that influence antihypertensive therapy selection and monitoring.
	 	 	 	 	 Demonstrate understanding of non-pharmacological interventions, such as dietary modifications, physical activity, weight loss, and sodium restriction.
	 	 	 	 	 Monitor therapeutic outcomes and adverse effects, and adjust therapy accordingly to optimize blood pressure control and minimize harm.
	 	 	 	 Recognize the pharmacist?s role in hypertension screening, patient education, medication adherence, and interprofessional care.
	 	 
	 	 - name: Venous thromboembolism, prevention, and treatment
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 	 Describe the pathophysiology and risk factors for venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE).
Classify VTE based on clinical presentation and risk stratification, including provoked vs. unprovoked events and transient vs. persistent risk factors.
Explain the therapeutic goals in VTE management, including:
Preventing thrombus extension and embolization
Reducing recurrence risk
Minimizing bleeding complications
Improving patient outcomes and quality of life
Identify pharmacological agents used in VTE prevention and treatment, including:
Unfractionated heparin (UFH)
Low-molecular-weight heparins (LMWHs)
Direct oral anticoagulants (DOACs)
Vitamin K antagonists (e.g., warfarin)
	 	 	 
	 	 	 - PHRM3102
Apply evidence-based guidelines to develop individualized VTE prevention and treatment plans for:
Hospitalized medical and surgical patients
Patients with cancer-associated thrombosis ---> Teir 3?
Patients with renal impairment or obesity ---> this is not Teir one or two - probs more 3 
Evaluate the appropriate duration of anticoagulation therapy based on patient-specific factors and VTE classification (e.g., 3 months vs. extended therapy).
Recognize the pharmacist?s role in:
VTE risk assessment and prophylaxis planning
Patient education on anticoagulant use and adherence
Monitoring for efficacy and adverse effects
Managing perioperative anticoagulation and bridging strategies
Interpret laboratory and clinical data to assess anticoagulant therapy effectiveness and safety, including INR, aPTT, anti-Xa levels, and signs of bleeding or recurrence. Teir 3?

	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Acute coronary syndromes
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM4101
	 	 	 - ''
	 	 
	 	 - name: Advanced cardiac life support
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Arrhythmias, ventricular
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM3102
	 	 
	 	 - name: Heart failure, acute decompensated
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM3102
	 	 
	 	 - name: Hypertensive crises
	 	 
	 	 - name: Peripheral artery disease
	 	 
	 	 - name: Stroke (ischemic, hemorrhagic, and transient ischemic attack)
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Valvular heart disease
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Pericarditis
	 	 
	 	 - name: Pulmonary hypertension

- system: Dermatologic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Acne vulgaris
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM4101
	 	 
	 	 - name: Dermatitis
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM4101
	 	 
	 	 - name: Wounds, minor (e.g., lacerations, punctures, bites, incisions, abrasions,
	 	 	 	 and avulsions)
	 	 	 subjects:
	 	 	 - PHRM2102
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Alopecia
	 	 
	 	 - name: Burn injuries, minor (e.g., sunburn, self-treated burns)
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Insect bites and stings, prevention and treatment
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Psoriasis
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM4101
	 	 
	 	 - name: Sun-induced skin disorders, prevention
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Warts, calluses, and corns
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Xerosis (dry skin)
	 	 	 subjects:
	 	 	 - PHRM2102
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Stevens-Johnson syndrome, toxic epidermal necrolysis
	 	 
	 	 - name: Wounds, major (e.g., pressure ulcers)
	 	 	 subjects:
	 	 	 - PHRM2102

- system: Ear, nose, mouth, and throat conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Allergic rhinitis
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 	 - PHRM1102
	 	 
	 	 - name: Common cold
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 	 - PHRM1102
	 	 
	 	 - name: Cough
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 	 - PHRM1102
	 	 
	 	 - name: Oral lesions (e.g., cold sores, aphthous ulcers)
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Otitis externa (e.g., swimmer's ear)
	 	 	 subjects:
	 	 	 - PHRM3101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Cerumen impaction
	 	 
	 	 - name: Xerostomia (dry mouth)
	 	 	 subjects:
	 	 	 - PHRM3101

- system: Endocrine conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Diabetes, type 2 (including prediabetes)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHR4101
	 	 
	 	 - name: Hypothyroidism
	 	 	 subjects:
	 	 	 - PHRM2101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Adrenal gland disorders
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Diabetes, type 1 (including latent autoimmune diabetes)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Gender-affirming therapy
	 	 
	 	 - name: Hyperglycemic crises
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Hyperthyroidism
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Male hypogonadism
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Diabetes secondary e.g., monogenic diabetes syndromes, cystic fibrosis,
	 	 	 	 pancreatitis, organ transplantation)
	 	 
	 	 - name: Pituitary gland disorders

- system: GI conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Anorectal disorders (e.g., hemorrhoids)
	 	 
	 	 - name: Constipation
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Diarrhea
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Drug dosing in hepatic dysfunction
	 	 
	 	 - name: Gastroesophageal reflux disease (including heartburn)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM4101
	 	 
	 	 - name: Nausea and vomiting, simple (e.g., acute viral gastroenteritis, overindulgence,
	 	 	 	 motion sickness)
	 	 	 subjects:
	 	 	 - PHRM2101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Cirrhosis, end-stage liver disease, and complications (e.g., portal hypertension,
	 	 	 	 ascites, varices, hepatic encephalopathy, hepatorenal syndrome)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Inflammatory bowel disease
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Irritable bowel syndrome
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Metabolic dysfunction-associated fatty liver disease
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Nausea and vomiting, complex (e.g., postoperative)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Pancreatitis
	 	 
	 	 - name: Peptic ulcer disease (including stress-related mucosal injury, GI bleeding)
	 	 	 subjects:
	 	 	 - PHRM2101

- system: Gynecologic and obstetric conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Contraception (including emergency contraception)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Drug safety in pregnancy and lactation
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM1102
	 	 
	 	 - name: Menopausal symptoms
	 	 	 subjects:
	 	 	 - PHRM2101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Diabetes, gestational
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Hypertensive disorders of pregnancy (e.g., pregnancy-induced hypertension,
	 	 	 	 preeclampsia, eclampsia)
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Labor and delivery (e.g., labor induction, preterm labor, pain management,
	 	 	 	 postpartum hemorrhage)
	 	 
	 	 - name: Menstrual cycle disorders (e.g., dysmenorrhea, menorrhagia, premenstrual
	 	 	 	 dysphoric disorder)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM1102 (dysmenorrhea - relevant to OTC)
	 	 
	 	 - name: Other pregnancy-induced and chronic conditions (e.g., constipation, gastroesophageal
	 	 	 	 reflux disease, nausea and vomiting, UTI)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Postpartum depression
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Pregnancy termination
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Endometriosis and uterine fibroids
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Female sexual dysfunction
	 	 
	 	 - name: Infertility
	 	 
	 	 - name: Polycystic ovary syndrome
	 	 	 subjects:
	 	 	 - PHRM2101

- system: Hematologic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Anemias (e.g., iron deficiency, vitamin B12deficiency, folic acid deficiency,
	 	 	 	 chronic disease/inflammation)
	 	 	 subjects:
	 	 	 - PHRM2102
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Heparin-induced thrombocytopenia
	 	 
	 	 - name: Sickle cell disease
	 	 	 subjects:
	 	 	 - PHRM2102
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Coagulation disorders (e.g., hemophilia, von Willebrand disease, antiphospholipid
	 	 	 	 syndrome, clotting factor deficiencies)
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Drug-induced hemolytic anemias
	 	 	 subjects:
	 	 	 - PHRM2102

- system: Immunologic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Allergies/drug hypersensitivities (e.g., anaphylaxis)
	 	 	 subjects:
	 	 	 - PHRM3101 (with respect to antibiotics)
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Drug desensitization (e.g., penicillin skin testing)
	 	 
	 	 - name: Solid organ transplantation
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 
	 	 - name: Systemic lupus erythematosus

- system: Infectious diseases and conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Clostridioides difficileinfection
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Common parasitic diseases (e.g., head and body lice, pinworm)
	 	 
	 	 - name: Fungal infections, superficial (e.g., vulvovaginal and oral/esophageal
	 	 	 	 candidiasis, dermatophytoses)
	 	 	 subjects:
	 	 	 - PHRM3101 (dermatophytoses)
	 	 
	 	 - name: Immunizations (including travel vaccinations)
	 	 	 subjects:
	 	 	 - PHRM3101 and PHRM3102
	 	 
	 	 - name: Influenza viral infection
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 	 - PHRM1102
	 	 
	 	 - name: Lower respiratory tract infections
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Skin and soft tissue infections
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Upper respiratory tract infections (e.g., otitis media, sinusitis, bronchitis,
	 	 	 	 pertussis)
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: UTIs, uncomplicated
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 	 - PHRM4101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Antimicrobial prophylaxis in surgery and other procedures
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Bloodstream and catheter infections
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Bone and joint infections
	 	 
	 	 - name: CNS infections (e.g., meningitis, encephalitis, brain abscess)
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Coronavirus disease 2019
	 	 	 subjects:
	 	 	 - PHRM3101 (I think PHRM3201 goes into the virus)
	 	 	 - PHRM1102
	 	 
	 	 - name: Fungal infections, invasive (e.g., endemic fungus, cryptococcosis, aspergillosis,
	 	 	 	 hematogenous candidiasis, mucormycosis)
	 	 
	 	 - name: GI infections (e.g., infectious diarrhea, enterotoxigenic poisonings)
	 	 	 subjects:
	 	 	 - PHRM3101 (H. pylori
	 	 	 - gastro
	 	 	 - giardia
	 	 	 - C. diff
	 	 	 - E. coli)
	 	 
	 	 - name: Hepatitis, viral
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: HIV infection (including pre- and postexposure prophylaxis)
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Infective endocarditis
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Intra-abdominal infections
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Opportunistic infections in patients with altered immunocompetence
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Sexually transmitted infections (e.g., syphilis, gonorrhea, chlamydia,
	 	 	 	 trichomoniasis, human papillomavirus, pelvic inflammatory disease)
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Tuberculosis
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: UTIs, complicated
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Viral infections (e.g., varicella, cytomegalovirus, herpes simplex, measles,
	 	 	 	 mumps, rabies)
	 	 	 subjects:
	 	 	 - PHRM3101 (not sure about CMV
	 	 	 - rabies might be in vaccination)
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Mycobacterial infections, other (leprosy, nontuberculous mycobacterial
	 	 	 	 infections)
	 	 
	 	 - name: Prostatitis
	 	 
	 	 - name: Tickborne illnesses (e.g., Lyme borreliosis, ehrlichiosis, Rocky Mountain
	 	 	 	 spotted fever, relapsing fever)
	 	 
	 	 - name: Travel medicine (including prevention and treatment)
	 	 	 subjects:
	 	 	 - PHRM3101 (a small amount in vaccination)

- system: Kidney, fluid, and electrolyte conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Chronic kidney disease, prevention of progression
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM4101
	 	 	 - PHRM3102
	 	 
	 	 - name: Drug dosing in altered kidney function (excluding dialysis)
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM4101
	 	 	 - PHRM3102
	 	 
	 	 - name: Electrolyte disorders (e.g., potassium, calcium, phosphorus, magnesium)
	 	 	 subjects:
	 	 	 - PHRM2102
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Acid-base disturbances
	 	 
	 	 - name: Acute kidney injury
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM3102
	 	 
	 	 - name: Chronic kidney disease, secondary complications
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM3102
	 	 
	 	 - name: Drug dosing in dialysis
	 	 
	 	 - name: Sodium and water disorders (including fluid management)
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Kidney replacement therapies
	 	 	 subjects:
	 	 	 - PHRM3101

- system: Musculoskeletal and connective tissue conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Gout and hyperuricemia
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Osteoarthritis
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Osteoporosis
	 	 	 subjects:
	 	 	 - PHRM2101
Describe the pathophysiology of osteoporosis, including the roles of bone remodeling, osteoclast and osteoblast activity, and hormonal influences (e.g., estrogen, parathyroid hormone).
Identify risk factors and populations at risk for osteoporosis, including postmenopausal women, older adults, individuals on long-term corticosteroids, and those with secondary causes (e.g., endocrine disorders).
Explain the clinical goals of osteoporosis management, including:
Reducing the risk of fragility fractures (hip, vertebral, and non-vertebral)
Improving or maintaining bone mineral density (BMD)
Minimizing adverse effects of therapy
Enhancing patient quality of life and functional independence

	 	 	 - PHRM3102
	 	 	 
Interpret diagnostic criteria and tools used in osteoporosis, including:
Dual-energy X-ray absorptiometry (DXA)
T-scores and Z-scores
FRAX score for fracture risk assessment
Describe pharmacological treatment options, including:
First-line agents: bisphosphonates (e.g., alendronate, risedronate)
Alternatives: denosumab, selective estrogen receptor modulators (SERMs), teriparatide, romosozumab
Calcium and vitamin D supplementation
Compare the mechanisms of action, efficacy, safety, and monitoring of osteoporosis medications.
Apply evidence-based guidelines to develop individualized treatment plans for patients with osteoporosis or low bone mass.
Evaluate non-pharmacological strategies for osteoporosis prevention and management, including:
Weight-bearing and resistance exercise
Fall prevention strategies
Lifestyle modifications (e.g., smoking cessation, alcohol moderation)
	 	 
	 	 - name: Soft tissue injuries (e.g., strains, sprains, myalgias)
	 	 	 subjects:
	 	 	 - PHRM1102 (OTC conditions)
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Rheumatoid arthritis
	 	 	 subjects:
	 	 	 - PHRM2101
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Rhabdomyolysis
	 	 	 subjects:
	 	 	 - PHRM2102 (in dyslipidaemias)

- system: Neurologic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Headache (e.g., tension-type, migraine, cluster)
	 	 	 subjects:
	 	 	 - PHRM1102 (Migraine
	 	 	 - Tension + OTC treatment options). PHRM3102
	 	 	 Explain the different types of headaches and its causes
	 	 	 Apply therapeutic knowledge of pain management to ensure appropriate management 
	 	 
	 	 - name: Pain, neuropathic (e.g., diabetic, postherpetic)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM1102 (relevant to OTC)
	 	 	 - PHRM3102
	 	 	 Explain the principles of pain management, with a focus on neuropathic pain
	 	 	 Describe the treatment options of neuropathic pain therapies

	 	 
	 	 
	 	 - name: Pain, nociceptive (acute and chronic)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM1102 (relevant to OTC)
	 	 	 - PHRM3102
	 ? Explain the principles of pain management, the complex nature of pain, and how to manage acute and chronic non-cancer pain. 
? Identify pain causes, pain types, and pain intensity.*
? Discuss the importance of appropriate analgesic selection and opioid stewardship. 
? Implement clinical knowledge to authentic pain cases which involve multimorbidity and other patient specific considerations. 
? Explain pain management, including the appropriate use of pain adjuvants and use of medicinal cannabis in the treatment of chronic non-cancer pain

	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Epilepsy
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 - PHRM3102
	 	 
	 	 - name: Essential tremor
	 	 
	 	 - name: Fibromyalgia
	 	 
	 	 - name: Multiple sclerosis
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 
	 	 - name: Neurocognitive disorders (e.g., Alzheimer disease, vascular dementia,
	 	 	 	 frontotemporal dementia)
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 Describe the pathophysiology and progression of Alzheimer?s disease and other common dementias (e.g., vascular, Lewy body, frontotemporal). 
	 	 	 Identify early and late clinical features of dementia, including cognitive, behavioural, and functional impairments.
	 	 	 Explain the therapeutic goals in the management of dementia, including:
	 	 	 	 Slowing cognitive decline
	 	 	 	 Managing behavioural and psychological symptoms
	 	 	 	 Preserving functional independence
	 	 	 	 Reducing caregiver burden and improving quality of life
	 	 	 	 Describe pharmacological treatment options, including:
	 	 	 	 Cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine)
	 	 	 	 NMDA receptor antagonists (e.g., memantine)
	 	 	 	 Agents for behavioural symptoms (e.g., antidepressants, antipsychotics[only if necessary and with caution]

	 	 	 - PHRM3102
	 	 Bulding on the above - in addition to describing and applying therapeutic options:
	 	 Compare the mechanisms of action, efficacy, safety, and monitoring of dementia medications.
	 	 Apply evidence-based guidelines to develop individualized treatment plans based on dementia type, stage, and patient-specific factors.
	 	 Evaluate non-pharmacological interventions, such as cognitive stimulation therapy, environmental modifications, and caregiver support strategies.
	 	 Recognize the pharmacist?s role in:
	 	 Educating patients and caregivers about disease progression and medication use
	 	 Monitoring for adverse effects and drug interactions
	 	 Supporting adherence and deprescribing when appropriate
	 	 Collaborating with multidisciplinary teams in dementia care
	 	 Interpret clinical and cognitive assessment tools, such as the MMSE, MoCA, and ADAS-Cog, to support diagnosis and monitor disease progression. 	 	
	 	 - name: Parkinson disease
	 	 	 subjects:
	 	 	 - PHRM2102
	 	 	 Describe the pathophysiology of Parkinson?s disease, including the role of dopaminergic neuron degeneration in the substantia nigra and its impact on motor control.
	 	 	 Identify the cardinal motor and non-motor symptoms of Parkinson?s disease, including tremor, rigidity, bradykinesia, postural instability, and neuropsychiatric manifestations.
Explain the therapeutic goals in the management of Parkinson?s disease, including:
Improving the patient?s ability to perform activities of daily living 1
Minimizing motor and non-motor symptom burden
Reducing medication-related complications (e.g., dyskinesias, motor fluctuations)
Enhancing quality of life and functional independence
Describe pharmacological treatment options, including:
Dopaminergic agents (e.g., levodopa/carbidopa)
Dopamine agonists, MAO-B inhibitors, COMT inhibitors
Anticholinergics and amantadine for specific symptom control

	 	 	 - PHRM3102
	 	 	 Compare the mechanisms of action, efficacy, side effects, and monitoring of antiparkinsonian medications.
Apply evidence-based guidelines to develop individualized treatment plans based on disease stage, symptom profile, and patient-specific factors.
Recognize the importance of medication timing and dietary considerations, particularly with levodopa and protein interactions.
Evaluate non-pharmacological interventions, including physiotherapy, occupational therapy, speech therapy, and surgical options (e.g., deep brain stimulation).
Demonstrate the pharmacist?s role in:
Educating patients and caregivers on medication use and adherence
Monitoring for adverse effects and drug interactions
Supporting multidisciplinary care and transitions between care settings
	 	 
	 	 - name: Sleep?éçwake disorders (e.g., narcolepsy, restless legs syndrome, circadian
	 	 	 	 rhythm disorders; see also ?é£Insomnia?éó in the Psychiatric and Behavioral
	 	 	 	 Conditions section)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Status epilepticus
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Amyotrophic lateral sclerosis
	 	 
	 	 - name: Huntington disease
	 	 
	 	 - name: Myasthenia gravis

- system: Nutritional conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Nutrient deficiency and excess (including vitamins and trace minerals)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Overweight and obesity
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 	 	 	 ? Understand Obesity as a Chronic Disease: Explain the pathophysiology, classification, and public health impact of obesity in Australia, including disparities in Indigenous populations.
	 	 	 	 	 	 	 Assess and Stratify Risk: Conduct comprehensive assessments, identify comorbidities, and determine appropriate interventions using Australian clinical guidelines.
	 	 	 	 	 	 	 Implement Lifestyle and Behavioural Strategies: Support patients in adopting evidence-based dietary, physical activity, and behavioural changes, using motivational interviewing and culturally sensitive approaches.
	 	 	 	 	 	 	 Apply Pharmacological and Surgical Interventions: Describe the mechanisms, indications, and monitoring of anti-obesity medications and bariatric procedures, including post-operative care and medication adjustments.
	 	 	 	 	 	 	 
	 	 	 - PHRM3102
	 	 	 	 	 	 	 Optimise Medication Management: Develop and monitor medication plans that minimise weight gain, manage comorbidities, and consider altered pharmacokinetics in obesity.
	 	 	 	 	 	 	 Promote Ethical and Professional Practice: Address weight stigma, use person-first language, and advocate for equitable, respectful care in diverse populations.

	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Malabsorptive syndrome (including metabolic surgical procedures)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Malnutrition prevention and treatment (e.g., enteral and parenteral nutrition)

- system: Oncologic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 Can we re-write these headings as at an undergraduate level I think we focus on overall management of cancer and cancer care from a 
	 	 pharmacists perspective

	 	 Describe the pathophysiology and epidemiology of common cancers in Australia (e.g., breast, colorectal, lung, prostate, melanoma).
Explain the principles of cancer staging and how they influence treatment decisions.
Identify the pharmacological classes of anticancer agents, including cytotoxics, targeted therapies, immunotherapies, and hormonal agents.
2. Patient-Centred Cancer Care
Apply patient-specific factors (e.g., age, comorbidities, performance status, pharmacogenomics) to select appropriate cancer therapies.
Communicate effectively with patients and interdisciplinary teams regarding cancer treatment plans, expected outcomes, and side effects.
Demonstrate cultural competence in cancer care, including considerations for Aboriginal and Torres Strait Islander peoples.
3. Medication Management and Monitoring
Develop and justify evidence-based medication management plans for patients undergoing chemotherapy, immunotherapy, or supportive care.
Monitor for and manage common adverse effects of cancer therapies (e.g., nausea, neutropenia, mucositis, cardiotoxicity).
Interpret laboratory and clinical data to assess treatment response and toxicity.

Discuss the expanding role of community pharmacists in managing patients receiving oral anti-cancer drugs
List common medication errors to reduce the risk of future medication errors occurring
Explain the common side effects, interactions and toxicities associated with oral anti-cancer drugs
	 	 
	 	 - name: Supportive care I (pain, nausea, vomiting, constipation, diarrhea, fatigue,
	 	 	 	 mucositis)

	 	 	 	 	 	 	 Describe the pathophysiology and causes of common adverse effects associated with cancer therapies, including chemotherapy, radiation, and targeted agents.
	 	 	 	 	 	 	 Explain the therapeutic goals of supportive care in oncology, including:
	 	 	 	 	 	 	 Preventing or minimizing treatment-related complications
	 	 	 	 	 	 	 Enhancing patient comfort and quality of life
	 	 	 	 	 	 	 Supporting treatment adherence and completion
	 	 	 	 	 	 	 Reducing hospitalizations and healthcare burden
	 	 	 	 	 	 	 Identify pharmacological and non-pharmacological strategies for managing:
	 	 	 	 	 	 	 Pain: Use of opioids, adjuvant analgesics, and individualized pain management plans
	 	 	 	 	 	 	 Nausea and vomiting: Classification (acute, delayed, anticipatory), antiemetic regimens (e.g., 5-HT3 antagonists, NK1 antagonists, corticosteroids)
	 	 	 	 	 	 	 Constipation: Laxatives, stool softeners, opioid-induced constipation management
	 	 	 	 	 	 	 Diarrhea: Antidiarrheals (e.g., loperamide), hydration, and dietary adjustments
	 	 	 	 	 	 	 Fatigue: Non-pharmacological interventions, psychostimulants, and anemia management
	 	 	 	 	 	 	 Mucositis: Oral hygiene, topical agents, cryotherapy, and pain control
	 	 	 	 	 	 	 Apply evidence-based guidelines to recommend appropriate supportive care interventions based on cancer type, treatment regimen, and patient-specific factors.
	 	 	 	 	 	 	 Evaluate the safety, efficacy, and monitoring requirements of supportive care medications, including potential drug interactions with anticancer therapies.
	 	 	 	 	 	 	 Recognize the pharmacist?s role in:
	 	 	 	 	 	 	 Educating patients and caregivers on symptom management
	 	 	 	 	 	 	 Monitoring for adverse effects and treatment complications
	 	 	 	 	 	 	 Collaborating with oncology teams to optimize supportive care
	 	 	 	 	 Interpret clinical scenarios and patient-reported outcomes to assess the need for supportive care interventions and adjust therapy accordingly.
	 
	 - tier: 2 - arguably this could be tier 3
	 	 conditions:
	 	 
	 	 - name: Breast cancer
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 	 	 	Describe the pathophysiology, molecular subtypes, and diagnostic tools used in breast cancer.
	 	 	 	 Explain the therapeutic goals of breast cancer treatment, including disease control, prevention of recurrence, and quality of life.
	 	 	 	 Identify and compare key treatment modalities, including endocrine therapy, chemotherapy, targeted therapy, and immunotherapy.
	 	 	 	 Apply evidence-based guidelines to develop and monitor individualized treatment plans.
	 	 	 	 Recognize the pharmacist?s role in patient education, adverse effect management, and multidisciplinary care. 	 	
	 	 - name: Colorectal cancer
	 	 	 subjects:
	 	 	 - PHRm3102
	 	 
	 	 - name: Gynecologic cancers (cervical, endometrial, ovarian)
	 	 
	 	 - name: Leukemias, acute and chronic
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Lung cancer
	 	 	 subjects:
	 	 	 - PHRM3102 - broadly not a key focus
	 	 
	 	 - name: Lymphomas (Hodgkin lymphoma, non-Hodgkin lymphoma)
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Melanoma
	 	 	 subjects:
	 	 	 - COvered in a case in Palliative care PHRM3102
	 	 
	 	 - name: Multiple myeloma
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Oncologic emergencies (e.g., tumor lysis syndrome, hypercalcemia, coagulopathy,
	 	 	 	 febrile neutropenia)
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 	 	 Describe the pathophysiology and clinical presentation of common oncologic emergencies, including tumor lysis syndrome, hypercalcemia of malignancy, coagulopathies, and febrile neutropenia.
	 	 	 	 Explain the therapeutic goals and urgency of managing oncologic emergencies to prevent morbidity and mortality.
	 	 	 	 Identify appropriate pharmacological and supportive interventions, including hydration, electrolyte management, antimicrobials, and specific antidotes (e.g., rasburicase, bisphosphonates, G-CSF).
	 	 	 	 Apply evidence-based protocols to assess, triage, and manage patients experiencing oncologic emergencies.
	 	 	 Recognize the pharmacist?s role in early detection, medication selection, monitoring, and interprofessional collaboration in acute oncology care. 	 	
	 	 - name: Prostate cancer
	 	 
	 	 - name: Supportive care II (e.g., myelosuppression, thrombosis, extravasation)
	 	 	 subjects:
	 	 	 - PHRM3102
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Bladder cancer
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Germ cell tumors
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Head and neck cancer
	 	 
	 	 - name: Hematopoietic stem cell transplantation, including complications
	 	 
	 	 - name: GI cancers, other (e.g., carcinoid, esophageal, gastric, hepatobiliary,
	 	 	 	 pancreatic)
	 	 
	 	 - name: Myelodysplastic syndromes
	 	 
	 	 - name: Renal cell carcinoma
	 	 
	 	 - name: Skin cancer, nonmelanoma (e.g., basal cell carcinoma, cutaneous squamous
	 	 	 	 cell carcinoma)

- system: Ophthalmic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Conjunctivitis (e.g., bacterial, viral, allergic)
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Keratoconjunctivitis sicca (dry eye syndrome)
	 	 	 subjects:
	 	 	 - PHRM3101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Glaucoma
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Bacterial keratitis
	 	 
	 	 - name: Blepharitis
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Corneal abrasions
	 	 
	 	 - name: Hordeolum (stye)
	 	 
	 	 - name: Macular degeneration
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Retinopathy

- system: Psychiatric and behavioral conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Anxiety disorders (e.g., generalized anxiety, panic, social anxiety disorder)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Depressive disorders (e.g., major depressive disorder)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Insomnia (see other sleep?éçwake disorders in the Neurologic Conditions
	 	 	 	 section)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Opioid use disorder (including opioid withdrawal)
	 	 	 subjects:
	 	 	 - PHRM4101
	 	 
	 	 - name: Tobacco/nicotine use disorder (including smoking cessation)
	 	 	 subjects:
	 	 	 - PHRM4101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Alcohol use disorder (including alcohol withdrawal)
	 	 
	 	 - name: Attention-deficit/hyperactivity disorder
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Bipolar disorder (e.g., mania, bipolar depression, maintenance therapy)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM3102
	 	 
	 	 - name: Delirium/acute agitation (non-critically ill patients)
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Schizophrenia
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM3102
	 	 
	 	 - name: Trauma- and stressor-related disorders (e.g., posttraumatic stress disorder)
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge-eating
	 	 	 	 disorder)
	 	 
	 	 - name: Obsessive-compulsive disorders
	 	 
	 	 - name: Substance use disorders, other (e.g., hallucinogens, stimulants, depressants,
	 	 	 	 performance-enhancing drugs)

- system: Respiratory conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Asthma
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Chronic obstructive pulmonary disease
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 	 - PHRM4101
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Cystic fibrosis
	 	 	 subjects:
	 	 	 - PHRM3101 (i think we have greatly reduced the content on CF compared to PHRM3012)
	 	 
	 	 - name: Obstructive sleep apnea
	 	 	 subjects:
	 	 	 - PHRM2101

- system: Urologic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Benign prostatic hypertrophy
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Erectile dysfunction
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM3102 has one case
	 	 
	 	 - name: Urinary incontinence (including overactive bladder)
	 	 	 subjects:
	 	 	 - PHRM3102

- system: Pediatrics
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Dehydration and oral replacement therapy
	 	 
	 	 - name: Fever
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 	 - PHRM1102 (relevant to OTC)
	 	 
	 	 - name: Pain relief
	 	 	 subjects:
	 	 	 - PHRM1102 (relevant to OTC)
	 	 
	 	 - name: Pediatric drug dosing
	 	 	 subjects:
	 	 	 - PHRM1102
	 	 	 - PHRM3102
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Bronchiolitis (including RSV)
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Neonatal and pediatric critical care (e.g., apnea of prematurity, bronchopulmonary
	 	 	 	 dysplasia, sepsis, respiratory distress syndrome)
	 	 	 subjects:
	 	 	 - PHRM3102
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Congenital heart disease (including patent ductus arteriosus)
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Enuresis
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Nutrient deficiency in infants and children
	 	 
	 	 - name: Pediatric advanced life support

- system: Older people
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Safe medication use in older people (e.g., tools for improving medication
	 	 	 	 safety [AGS Beers, STOPP/START, STEADI-Rx], drug dosing and monitoring, PIMs,
	 	 	 	 deprescribing)
	 	 	 subjects:
	 	 	 - PHRM4101
	 	 	 - PHRM3102

- system: Critically ill
	 tiers:

	 	 Understand the Scope and Role of the Critical Care Pharmacist: Describe the evolution and impact of pharmacy practice in intensive care units (ICUs), including levels of pharmacist involvement.
	 	 Recognise the pharmacist?s role in improving outcomes in high-acuity conditions such as sepsis, ARDS, and multi-organ failure.
	 	 Apply Clinical and Pharmacological Knowledge in Critical Illness
	 	 Explain the pathophysiology and pharmacotherapy of common ICU conditions, with a focus on ARDS, sepsis, acute kidney injury, and shock.
	 	 Optimise drug dosing using pharmacokinetic and pharmacodynamic principles in critically ill patients, including those on mechanical ventilation or extracorporeal support.
	 	 Deliver Evidence-Based, Patient-Centred Care: Develop and monitor medication regimens tailored to the dynamic needs of ICU patients, including those with ARDS.
	 	 Collaborate in Multidisciplinary ICU Teams: Communicate effectively with intensivists, nurses, and allied health professionals to contribute to team-based care.

	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Acute respiratory distress syndrome
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: CNS trauma
	 	 
	 	 - name: Pain, agitation, and delirium
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Respiratory support (including rapid sequence intubation)
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Sepsis
	 	 	 subjects:
	 	 	 - PHRM3101
	 	 
	 	 - name: Shock syndromes
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Burns, major/severe
	 	 
	 	 - name: Extracorporeal membrane oxygenation, pharmacologic considerations
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Mechanical circulatory support devices, pharmacologic considerations
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Post-intensive care syndrome
	 	 
	 	 - name: Subarachnoid hemorrhage, aneurysmal
	 	 	 subjects:
	 	 	 - PHRM2102

- system: Terminally ill
	 tiers:
	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: End-of-life care and symptom management
	 	 	 subjects:
	 	 	 - PHRM3102
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Medical aid in dying
	 	 	 subjects:
	 	 	 - PHRM3102

- system: Toxicologic conditions
	 tiers:
	 
	 - tier: 1
	 	 conditions:
	 	 
	 	 - name: Acetaminophen toxicity
	 	 	 subjects:
	 	 	 - PHRM3102
Identify the stages and symptoms of paracetamol poisoning. 
Describe the metabolism of paracetamol and the mechanism of hepatotoxicity. 
Recognize risk factors that increase the likelihood of liver damage. 
Outline treatment strategies including the use of N-acetylcysteine (NAC). 
Interpret paracetamol levels using the treatment nomogram. 
Discuss the importance of early intervention and patient education. 
Explain the pharmacist?s role in prevention and management of overdose.

	 	 - name: Opioid overdose
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 	 - PHRM3102
1. Recognise and Respond to Opioid Overdose
* Identify clinical signs and symptoms of opioid toxicity and distinguish it from other toxidromes.
* Apply evidence-based protocols for the acute management of opioid overdose, including airway support and naloxone administration.
2. Optimise Pharmacological Interventions
* Explain the pharmacology, dosing, routes of administration, and monitoring of naloxone in various settings.
* Evaluate the role of long-acting opioid antagonists and supportive therapies in overdose management.
3. Promote Safe and Ethical Practice
* Counsel patients and caregivers on naloxone use, overdose prevention, and harm minimisation strategies.
* Address stigma and ethical considerations in the care of individuals with opioid use disorder or overdose history.

	 
	 - tier: 2
	 	 conditions:
	 	 
	 	 - name: Anticoagulation overdose and reversal
	 	 	 subjects:
	 	 	 - PRHM3102
1. Understand Anticoagulant Toxicity
* Describe the mechanisms, risks, and clinical signs of overdose for warfarin, DOACs, and heparins.
2. Assess and Monitor Bleeding
* Interpret coagulation tests (e.g., INR, aPTT) and recognise signs of minor and major bleeding.
3. Apply Reversal Strategies
* Select and administer appropriate reversal agents (e.g., vitamin K, PCC, idarucizumab) based on the anticoagulant and clinical scenario.
4. Optimise Patient Safety
* Adjust therapy post-reversal and counsel patients on safe anticoagulant use and bleeding risk.
5. Collaborate in Acute Care
* Contribute to emergency and critical care teams managing anticoagulant toxicity and support institutional safety protocols.

	 	 
	 	 - name: Antidepressant overdose (including serotonin syndrome)
	 	 	 subjects:
	 	 	 - PHRM2101
	 	 
	 	 - name: Antihypertensive medication toxicity
	 	 
	 	 - name: Benzodiazepine overdose
	 	 	 subjects:
	 	 	 - PHRM3102
1. Understand Benzodiazepine Pharmacology and Toxicity
* Describe the mechanism of action, therapeutic uses, and toxic effects of benzodiazepines, including risk factors for overdose.
2. Recognise and Assess Toxicity
* Identify clinical features of benzodiazepine toxicity (e.g., CNS depression, respiratory compromise) and interpret relevant assessments (e.g., tox screens, vital signs, GCS).
3. Manage Acute Toxicity
* Apply appropriate management strategies, including supportive care and the use of flumazenil, with consideration of risks and contraindications.
4. Promote Safe Use and Harm Reduction
* Counsel patients on safe benzodiazepine use, tapering strategies, and overdose prevention, particularly in populations at risk (e.g., elderly, polypharmacy, substance use disorder).
5. Collaborate in Acute and Community Care
* Contribute to multidisciplinary care in emergency and mental health settings, and support public health initiatives related to benzodiazepine safety and misuse prevention

	 	 
	 	 - name: Digoxin toxicity
	 	 	 subjects:
	 	 	 - PHRM3102
1. 	 	 Understand Digoxin Pharmacology and Toxicity
* Describe the mechanism of action, therapeutic range, and toxic effects of digoxin, including risk factors for toxicity.
2. Recognise and Assess Toxicity
* Identify clinical signs of digoxin toxicity (e.g., nausea, visual disturbances, arrhythmias) and interpret relevant lab results (e.g., serum digoxin levels, electrolytes, ECG).
3. Manage Acute and Chronic Toxicity
* Apply evidence-based strategies for managing digoxin toxicity, including dose adjustment, electrolyte correction, and use of digoxin-specific antibody fragments (Digibind).
4. Optimise Patient Safety
* Counsel patients on safe digoxin use, adherence, and monitoring, especially in populations at higher risk (e.g., elderly, renal impairment).
5. Collaborate in Acute and Ongoing Care
* Work with healthcare teams to manage digoxin toxicity in emergency and inpatient settings, and support long-term medication safety and monitoring.

	 	 - name: Salicylate poisoning
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Sympathomimetic toxicity (e.g., cocaine, amphetamines, novel synthetic
	 	 	 	 cathinones)
	 	 	 subjects:
	 	 	 - PHRM3102
1. 	 	 Understand Sympathomimetic Agents and Toxicity
* Describe the pharmacology, mechanisms of toxicity, and common sources of sympathomimetic agents (e.g., cocaine, amphetamines, synthetic cathinones).
2. Recognise and Assess Toxicity
* Identify clinical features of toxicity (e.g., agitation, hypertension, hyperthermia, arrhythmias) and interpret relevant investigations (e.g., ECG, tox screens, vital signs).
3. Manage Acute Toxicity
* Apply evidence-based treatment strategies, including sedation, cooling, cardiovascular support, and management of complications such as seizures or rhabdomyolysis.
4. Promote Harm Reduction and Safe Practice
* Counsel patients on the risks of recreational and illicit drug use, and support harm minimisation strategies in collaboration with public health services.
5. Collaborate in Emergency and Mental Health Care
* Work with multidisciplinary teams in acute care settings to manage toxicity and support ongoing care, including mental health and substance use services.

	 	 - name: Toxic alcohol poisoning (e.g., ethylene glycol, methanol)
	 	 	 subjects:
	 	 	 - PHRM3102
	 
	 - tier: 3
	 	 conditions:
	 	 
	 	 - name: Anticholinergic toxicity (e.g., atropine, antimuscarinic chemical weapons)
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Cannabinoid toxicity
	 	 	 subjects:
	 	 	 - PHRM3102
	 	 
	 	 - name: Cholinergic toxicity (e.g., anticholinesterase insecticides, nerve agent
	 	 	 	 chemical weapons)
	 	 	 subjects:
	 	 	 - PHRM3102
Identify symptoms	of cholinergic toxicity 
Explain mechanisms	of cholinesterase inhibitor toxicity
Differentiate	from similar conditions using clinical reasoning 
Apply treatment protocols	including antidotes
Interpret diagnostics	like cholinesterase levels ? Not sure if this is needed ? to check with JB
	 	 
	 	 - name: Envenomations
	 	 	 subjects:
	 	 	 - PHRM3102
Identify the signs and symptoms	of common envenomations in Australia, including those from snakes, spiders, and jellyfish.
Describe how venoms affect the body, including their toxicological and pharmacological actions.
Distinguish envenomation syndromes	from other medical emergencies with similar presentations.
Outline appropriate treatment strategies, including the use of antivenoms and supportive care.
Interpret clinical and laboratory findings	to assist in diagnosis and monitor treatment progress.
Explain the pharmacist?s role	in emergency care and collaboration with healthcare teams during envenomation cases.

NB: I think Tox should be one topic with combined LOs vs separate LOs for each toxic agent ? it forms one week of content and is combined with crit care

Palliative Care 
Tier 2?
PHRM3102
Understand the goals and principles of palliative care, including comfort, dignity, and quality of life.
Recognize common symptoms managed in palliative care, such as pain, nausea, breathlessness, and anxiety.
Describe the role of pharmacists in medication management and deprescribing in palliative settings.
Identify appropriate use of opioids and adjuvant therapies for symptom control.
Communicate effectively and compassionately with patients, families, and healthcare teams.
Understand ethical and legal considerations in end-of-life care, including advance care planning.
Support culturally sensitive and patient-centered care in diverse populations
